Adamas Pharmaceuticals, Inc. (ADMS) Tops Q2 EPS by 7c

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) reported Q2 EPS of $0.88, $0.07 better than the analyst estimate of $0.81. Revenue for the quarter came in at $25.15 million versus the consensus estimate of $18.75 million.

For earnings history and earnings-related data on Adamas Pharmaceuticals, Inc. (ADMS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• SanDisk upgraded at JPMorgan after investor day; shares climb